

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Andrea D. Branch, *et al.*

Serial No.: 09/719,277

Filed: April 13, 2001

For: *NOVEL HEPATITIS C VIRUS PEPTIDES AND
USES THEREOF*

Attorney Docket No.: RII-003CPUS

Group Art Unit: 1648

Examiner: T. Brown

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 553863125 US, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 19, 2005

Signature: 

(Megan E. Williams)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney are aware of the following additional publications, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Please charge the appropriate fee of \$180.00 to our Deposit Order Account No. 12-0080. No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


A handwritten signature in black ink, appearing to read 'M. E. Williams', is written over a horizontal line.

Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: May 19, 2005

GAD/MEW/rl
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/719,277
				Filing Date	April 13, 2001
				First Named Inventor	Andrea D. Branch, <i>et al.</i>
				Art Unit	1648
				Examiner Name	T. Brown
Sheet	1	of	2	Attorney Docket Number	RII-003CPUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D1	Boulant, S., <i>et al.</i> "Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from Genotype 1b." <i>J Biol Chem.</i> 2003 Nov 14; 278(46):45785-92.	
	D2	Branch, A.D., <i>et al.</i> "The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others." <i>Semin Liver Dis.</i> 2005 Feb; 25(1):105-17.	
	D3	Choi, J., <i>et al.</i> "Triple decoding of hepatitis C virus RNA by programmed translational frameshifting." <i>Mol Cell Biol.</i> 2003 Mar; 23(5):1489-97.	
	D4	Komurian-Pradel, F., <i>et al.</i> "Antigenic relevance of F protein in chronic hepatitis C virus infection." <i>Hepatology.</i> 2004 Oct; 40(4):900-9.	
	D5	Ogata, S., <i>et al.</i> "Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma." <i>J Clin Microbiol.</i> 2002 Oct; 40(10):3625-30.	
	D6	Roussel, J., <i>et al.</i> "Characterization of the expression of the Hepatitis C virus F protein." <i>J Virol.</i> 2003; 84:1751-1759.	
	D7	Tan, S-L., <i>et al.</i> "Hepatitis C therapeutics: current status and emerging strategies." <i>Nature.</i> 2002 Nov; 1:867-881.	
	D8	Vassilaki, N. <i>et al.</i> "Two alternative translation mechanisms are responsible for the expression of the HCV ARF/F/Core +1 coding open reading frame." <i>J Biol Chem.</i> 2003 Oct; 278: 40503-40513.	
	D9	Walewski, J.L., <i>et al.</i> "Reading between the lines: evidence for a new Hepatitis C virus protein." <i>Hepatology.</i> 2003 Sep; 36(3):757-60.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/719,277
				Filing Date	April 13, 2001
				First Named Inventor	Andrea D. Branch, <i>et al.</i>
				Art Unit	1648
				Examiner Name	T. Brown
Sheet	2	of	2	Attorney Docket Number	RII-003CPUS

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	D10	Walewski, J.L., <i>et al.</i> "Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions." <i>RNA</i> . 2002 May; 8(5):557-71.		
	D11	Walewski, J.L., <i>et al.</i> "Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame." <i>RNA</i> . 2001 May; 7(5):710-21.		
	D12	Walewski, J.L., <i>et al.</i> "HCV patients have antibodies against a novel protein encoded in a second reading frame." <i>Hepatology</i> . 1998 Oct; 27A#462.		
	D13	Xu, Z., <i>et al.</i> "Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum." <i>J Virol</i> . 2003 Jan; 77(2):1578-83.		
	D14	Yeh, C-T, <i>et al.</i> "Amino acid substitutions in codons 9-11 of hepatitis C virus core protein lead to the synthesis of a short core protein product." <i>J Gastroenterol Hepatol</i> . 2000 Feb; 15(2):182-91.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--